Inhibiting PARP as a Strategic Target in Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Inhibiting PARP as a Strategic Target in Cancer PDF full book. Access full book title Inhibiting PARP as a Strategic Target in Cancer by Christina Annunziata. Download full books in PDF and EPUB format.
Author: Christina Annunziata Publisher: Frontiers Media SA ISBN: 288919955X Category : Medicine (General) Languages : en Pages : 99
Book Description
Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage.
Author: Christina Annunziata Publisher: Frontiers Media SA ISBN: 288919955X Category : Medicine (General) Languages : en Pages : 99
Book Description
Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage.
Author: David A. Frank Publisher: Springer Science & Business Media ISBN: 1402073402 Category : Medical Languages : en Pages : 358
Book Description
One of the most exciting areas of cancer research now is the development of agents which can target signal transduction pathways that are activated inappropriately in malignant cells. The understanding of the molecular abnormalities which distinguish malignant cells from their normal counterparts has grown tremendously. This volume summarizes the current research on the role that signal transduction pathways play in the pathogenesis of cancer and how this knowledge may be used to develop the next generation of more effective and less toxic anticancer agents. Series Editor comments: "The biologic behavior of both normal and cancer cells is determined by critical signal transduction pathways. This text provides a comprehensive review of the field. Leading investigators discuss key molecules that may prove to be important diagnostic and/or therapeutic targets."
Author: Mark R. Kelley Publisher: Academic Press ISBN: 0128035994 Category : Science Languages : en Pages : 466
Book Description
DNA Repair and Cancer Therapy: Molecular Targets and Clinical Applications, Second Edition provides a comprehensive and timely reference that focuses on the translational and clinical use of DNA repair as a target area for the development of diagnostic biomarkers and the enhancement of cancer treatment. Experts on DNA repair proteins from all areas of cancer biology research take readers from bench research to new therapeutic approaches. This book provides a detailed discussion of combination therapies, in other words, how the inhibition of repair pathways can be coupled with chemotherapy, radiation, or DNA damaging drugs. Newer areas in this edition include the role of DNA repair in chemotherapy induced peripheral neuropathy, radiation DNA damage, Fanconi anemia cross-link repair, translesion DNA polymerases, BRCA1-BRCA2 pathway for HR and synthetic lethality, and mechanisms of resistance to clinical PARP inhibitors. - Provides a comprehensive overview of the basic and translational research in DNA repair as a cancer therapeutic target - Includes timely updates from the earlier edition, including Fanconi Anemia cross-link repair, translesion DNA polymerases, chemotherapy induced peripheral neuropathy, and many other new areas within DNA repair and cancer therapy - Saves academic, medical, and pharma researchers time by allowing them to quickly access the very latest details on DNA repair and cancer therapy - Assists researchers and research clinicians in understanding the importance of the breakthroughs that are contributing to advances in disease-specific research
Author: G.J.L. Kaspers Publisher: Springer Science & Business Media ISBN: 9780306460555 Category : Medical Languages : en Pages : 664
Book Description
Cellular drug resistance is a major limitation to the success of chemotherapy of leu kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in formation is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance.
Author: Sara Hurvitz Publisher: Elsevier Health Sciences ISBN: 0323581234 Category : Medical Languages : en Pages : 265
Book Description
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies.
Author: Csaba Szabo Publisher: CRC Press ISBN: 1420038893 Category : Medical Languages : en Pages : 354
Book Description
Poly (ADP-ribose) polymerase (PARP), also termed poly (ADP-ribose) synthetase (PARS) is a nuclear enzyme with a wide range of functions, including regulation of DNA repair, cell differentiation, and gene expression. More than a decade after the identification of PARP-like enzymatic activities in mammalian cells, a novel role was proposed for this e
Author: World Health Organization Publisher: ISBN: 9789283224068 Category : Cancer Languages : en Pages : 0
Book Description
Presents data on cancer incidence gathered from five population-based cancer registries in different regions of Thailand and compares these data with data on cancer incidence from other parts of the world. Apart from offering a comprehensive overview of cancer incidence in Thailand, the book uncovers a number of geographical differences in incidence, suggesting important behavioral, environmental, or industrial risk factors that deserve further study. Survival data from two registries are also presented and discussed. The opening chapters provide background information about the country and its population, describe the sources of data maintained in the five registries, and discuss the methods of data coding and analysis used in the study. Against this background, results are presented separately for each of 15 cancers and for childhood cancer. For each cancer, the number of cases registered in 1992-1994 is shown by sex, with age-specific incidence rates and some summary rates. The study uncovered striking geographical variations in the incidence of specific cancers. For the country as a whole, the highest incidences were found for cancers of the liver, lung, colon and rectum, oral cavity, bladder, stomach, leukaemia, non-Hodgkin lymphoma, and cancers of the nasopharynx and oesophagus. For each cancer, data are set out in numerous tables, compared with findings from other countries and discussed in terms of possible risk factors. Primary cancer of the liver was identified as the leading cancer of males and the third most important cancer in females.
Author: Gw Sledge Publisher: Clinical Pub ISBN: 9781846920660 Category : Breast Languages : en Pages : 0
Book Description
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author: Antoinette R. Tan, MD, MHSc Publisher: Demos Medical Publishing ISBN: 1617050431 Category : Medical Languages : en Pages : 244
Book Description
Breast Cancer: Breast cancer is second only to lung cancer as the leading cancer cause of death in women. In 2010 207,000 women will be diagnosed with breast cancer and over 39,000 are expected to die from breast cancer. Nevertheless, ongoing research and recent advances in both diagnostic and therapeutic modalities continue to make breast cancer management a rapidly evolving area in which the practitioner will want to be fully updated on current developments. Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and prevention strategies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer. With this volume the oncology practitioner will have a full and current overview of all significant current trends in this important area of oncology. About the Series: Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. Features of Emerging Cancer Therapeutics include: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice
Author: Christina Annunziata
Author: Christina Annunziata
Author: David A. Frank
Author: Mark R. Kelley
Author: G.J.L. Kaspers
Author: Sara Hurvitz
Author: Csaba Szabo
Author: World Health Organization
Author: Gw Sledge
Author: Lixiang Xue
Author: Antoinette R. Tan, MD, MHSc